Good News! Suzhou Shengji Pharmaceutical Co., Ltd. was recognized as a potential unicorn enterprise in Jiangsu High-tech Industrial Development Zone in 2021.

Recently, Jiangsu Productivity Promotion Center issued a notice on the asses**ent results of unicorn enterprises and gazelle enterprises in Jiangsu High-tech Industrial Development Zone in 2021, and Suzhou Shengji Pharmaceutical Co., Ltd. was honored to be named as a potential unicorn enterprise in Jiangsu High-tech Zone in 2021. This is the affirmation and recognition of the company's strength.

As a R&D and industrial manufacturing company, Suzhou Shengji Pharmaceutical Co., Ltd. is dedicated to the development of a series of reproductive health products, with its core technology being the R&D and industrialization of new glycoprotein hormone-based drugs. Up to now, two of the company's glycoprotein hormone drugs have entered clinical studies, and three pipelines are in various stages of preclinical studies. In the next three years, Shengji Pharmaceuticals will actively promote the research and development of each product, clinical trials, and the construction of industrialization bases, so as to provide complete solutions for the reproductive health of people of childbearing age in China as early as possible. “The road is long and the way is far, I will go up and down to find a way.” The Company will live up to its expectations, bear in mind its corporate mission, make persistent efforts, and give full play to the innovative and leading role of unicorn enterprises in high-quality development.

Article Related Links:https://www.jspc.org.cn/art/2021/11/26/art_335_16380.html